Following a central nervous system (CNS) injury including stroke, inflammation is a complex but crucial part of the body’s response. Although the extent of inflammation correlates with stroke severity, anti-inflammatory drugs have shown limited success in clinical trials. In fact, blocking the entry of inflammatory cells, such as monocytes, into the brain hindered the recovery process. This highlights the dual role of these immune cells, which differentiate into monocyte-derived macrophages (M-Mϕ) at the site of injury. These M-Mϕ are essential for both initiating and resolving the inflammatory response. The ability of the macrophages to switch their function and phenotype, from inflammatory to pro-resolving, renders them as a promising therapeutic target for inflammatory diseases. A critical step in this resolution is efferocytosis: the orchestrated clearance of apoptotic cells by phagocytes. This process is mediated by interactions between cellular danger signals and pattern recognition receptors (PRRs), which ultimately trigger the macrophage’s shift toward a resolving phenotype. This review will delve into the roles of PRRs and macrophage phenotypic changes, the importance of continuous efferocytosis, and the potential of enhancing efferocytosis as a therapeutic strategy for inflammatory diseases with a focus on cerebral ischemia.
ReedJC.Dysregulation of apoptosis in cancer. J Clin Oncol1999; 17: 2941–2953.
2.
KawanoMNagataS.Efferocytosis and autoimmune disease. Int Immunol2018; 30: 551–558.
3.
ElliottMRRavichandranKS.Clearance of apoptotic cells: implications in health and disease. J Cell Biol2010; 189: 1059–1070.
4.
DoranACYurdagulAJrTabasI.Efferocytosis in health and disease. Nat Rev2020; 20: 254–267.
5.
Perez-GarijoAStellerH.Spreading the word: non-autonomous effects of apoptosis during development, regeneration and disease. Development2015; 142: 3253–3262.
6.
TheryCOstrowskiMSeguraE.Membrane vesicles as conveyors of immune responses. Nat Rev Immunol2009; 9: 581–593.
7.
DiekerJTelJPieterseE, et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol2016; 68: 462–472.
8.
BhattacharyaPDhawanUKHussainMT, et al. Efferocytes release extracellular vesicles to resolve inflammation and tissue injury via prosaposin-GPR37 signaling. Cell Rep2023; 42: 112808.
9.
MedinaCBMehrotraPArandjelovicS, et al. Metabolites released from apoptotic cells act as tissue messengers. Nature2020; 580: 130–135.
10.
ParkKWJuHKimID, et al. Delayed infiltration of peripheral monocyte contributes to phagocytosis and transneuronal degeneration in chronic stroke. Stroke2022; 53: 2377–2388.
11.
GelderblomMLeypoldtFSteinbachK, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke2009; 40: 1849–1857.
12.
PlanasAM.Role of immune cells migrating to the ischemic brain. Stroke2018; 49: 2261–2267.
13.
KimEChoS.CNS and peripheral immunity in cerebral ischemia: partition and interaction. Exp Neurol2021; 335: 113508.
14.
IadecolaCBuckwalterMSAnratherJ.Immune responses to stroke: mechanisms, modulation, and therapeutic potential. J Clin Invest2020; 130: 2777–2788.
15.
NgaiDSchilperoortMTabasI.Efferocytosis-induced lactate enables the proliferation of pro-resolving macrophages to mediate tissue repair. Nat Metab2023; 5(12): 2206–2219.
16.
JuHParkKWKimID, et al. Phagocytosis converts infiltrated monocytes to microglia-like phenotype in experimental brain ischemia. J Neuroinflammation2022; 19: 190.
17.
ZhouLLuYQiuX, et al. Lipid droplet efferocytosis attenuates proinflammatory signaling in macrophages via TREM2- and MS4A7-dependent mechanisms. Cell Rep2025; 44: 115310.
18.
ZengLWangYHuangY, et al. IRG1/itaconate enhances efferocytosis by activating Nrf2–TIM4 signaling pathway to alleviate con A induced autoimmune liver injury. Cell Commun Signal2025; 23: 63.
19.
XieXDDongSSLiuRJ, et al. Mechanism of efferocytosis in determining ischaemic stroke resolution-diving into microglia/macrophage functions and therapeutic modality. Mol Neurobiol2024; 61: 7583–7602.
20.
ChenWZhangYZhaiX, et al. Microglial phagocytosis and regulatory mechanisms after stroke. J Cereb Blood Flow Metab2022; 42: 1579–1596.
21.
YangSMinCMoonH, et al. Internalization of apoptotic cells during efferocytosis requires Mertk-mediated calcium influx. Cell Death Dis2023; 14: 391.
22.
CaiBKasikaraCDoranAC, et al. MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity. Sci Signal2018; 11: eaar3721.
23.
LantzCBeckerADeBergeM, et al. Early-age efferocytosis directs macrophage arachidonic acid metabolism for tissue regeneration. Immunity2025; 58: 344–361.e7.
24.
ThorpECuiDSchrijversDM, et al. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe−/− mice. Arterioscler Thromb Vasc Biol2008; 28: 1421–1428.
25.
FourgeaudLTravesPGTufailY, et al. TAM receptors regulate multiple features of microglial physiology. Nature2016; 532: 240–244.
26.
ZhaoXSunGZhangJ, et al. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol2007; 61: 352–362.
27.
ZhaoXSunGTingSM, et al. Cleaning up after ICH: the role of Nrf2 in modulating microglia function and hematoma clearance. J Neurochem2015; 133: 144–152.
28.
TingSMZhaoXSunG, et al. Brain cleanup as a potential target for poststroke recovery: the role of RXR (retinoic X receptor) in phagocytes. Stroke2020; 51: 958–966.
29.
Nakahashi-OdaCFujiyamaSNakazawaY, et al. CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke. Sci Immunol2021; 6: eabe7915.
30.
TakimotoCHChaoMPGibbsC, et al. The macrophage “do not eat me” signal, CD47, is a clinically validated cancer immunotherapy target. Ann Oncol2019; 30: 486–489.
31.
WillinghamSBVolkmerJPGentlesAJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A2012; 109: 6662–6667.
32.
HuMLinYMenX, et al. High-salt diet downregulates TREM2 expression and blunts efferocytosis of macrophages after acute ischemic stroke. J Neuroinflammation2021; 18: 90.
33.
LvJJWangHZhangC, et al. CD147 sparks atherosclerosis by driving M1 phenotype and impairing efferocytosis. Circ Res2024; 134: 165–185.
34.
FanPLLaiHQWangHY, et al. CKLF1 disrupts microglial efferocytosis following acute ischemic stroke by binding to phosphatidylserine. Cell Death Differ2025; 32: 1499–1517.
35.
CaoX.Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol2016; 16: 35–50.
36.
FuryWParkKWWuZ, et al. Sustained increases in immune transcripts and immune cell trafficking during the recovery of experimental brain ischemia. Stroke2020; 51: 2514–2525.
37.
Garcia-BonillaLShahanoorZSciortinoR, et al. Analysis of brain and blood single-cell transcriptomics in acute and subacute phases after experimental stroke. Nat Immunol2024; 25: 357–370.
38.
PeregoCFumagalliSDe SimoniMG.Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J Neuroinflammation2011; 8: 174.
39.
TakeuchiOAkiraS.Pattern recognition receptors and inflammation. Cell2010; 140: 805–820.
40.
Tajalli-NezhadSKarimianMBeyerC, et al. The regulatory role of toll-like receptors after ischemic stroke: neurosteroids as TLR modulators with the focus on TLR2/4. Cell Mol Life Sci2019; 76: 523–537.
41.
CasoJRPradilloJMHurtadoO, et al. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation2007; 115: 1599–1608.
42.
TangSCArumugamTVXuX, et al. Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A2007; 104: 13798–13803.
43.
FangHWangPFZhouY, et al. Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury. J Neuroinflammation2013; 10: 27.
LiHYYuanZYWangYG, et al. Role of baicalin in regulating toll-like receptor 2/4 after ischemic neuronal injury. Chin Med J2012; 125: 1586–1593.
46.
HanPPHanYShenXY, et al. NLRP3 inflammasome activation after ischemic stroke. Behav Brain Res2023; 452: 114578.
47.
FrankeMBieberMKraftP, et al. The NLRP3 inflammasome drives inflammation in ischemia/reperfusion injury after transient middle cerebral artery occlusion in mice. Brain Behav Immun2021; 92: 223–233.
48.
BellutMBieberMKraftP, et al. Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice. J Neuroinflammation2023; 20: 4.
49.
WangQKohlsWWillsM, et al. A novel stroke rehabilitation strategy and underlying stress granule regulations through inhibition of NLRP3 inflammasome activation. CNS Neurosci Ther2024; 30: e14405.
50.
PanbhareKPandeyRChauhanC, et al. Role of NLRP3 inflammasome in stroke pathobiology: current therapeutic avenues and future perspective. ACS Chem Neurosci2024; 15: 31–55.
51.
YeXCHaoQMaWJ, et al. Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice. J Neuroinflammation2020; 17: 17.
52.
WanHHeMChengC, et al. Clec7a worsens long-term outcomes after ischemic stroke by aggravating microglia-mediated synapse elimination. Adv Sci2024; 11: e2403064.
Jimenez-DalmaroniMJXiaoNCorperAL, et al. Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS One2009; 4: e7411.
55.
FebbraioMHajjarDPSilversteinRL.CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest2001; 108: 785–791.
56.
ZaniIAStephenSLMughalNA, et al. Scavenger receptor structure and function in health and disease. Cells2015; 4: 178–201.
57.
GudgeonJMarin-RubioJLTrostM.The role of macrophage scavenger receptor 1 (MSR1) in inflammatory disorders and cancer. Front Immunol2022; 13: 1012002.
58.
GoldsteinJLHoYKBasuSK, et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A1979; 76: 333–337.
59.
NeyenCPluddemannARoversiP, et al. Macrophage scavenger receptor A mediates adhesion to apolipoproteins A–I and E. Biochemistry2009; 48: 11858–11871.
60.
HuangFLShiaoYJHouSJ, et al. Cysteine-rich domain of scavenger receptor AI modulates the efficacy of surface targeting and mediates oligomeric Abeta internalization. J Biomed Sci2013; 20: 54.
61.
Santiago-GarciaJKodamaTPitasRE.The class A scavenger receptor binds to proteoglycans and mediates adhesion of macrophages to the extracellular matrix. J Biol Chem2003; 278: 6942–6946.
62.
TodtJCHuBCurtisJL.The scavenger receptor SR-A I/II (CD204) signals via the receptor tyrosine kinase Mertk during apoptotic cell uptake by murine macrophages. J Leukoc Biol2008; 84: 510–518.
63.
ShichitaTItoMMoritaR, et al. MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. Nat Med2017; 23: 723–732.
64.
TianKOguraSLittlePJ, et al. Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Ann N Y Acad Sci2019; 1443: 34–53.
65.
XuSOguraSChenJ, et al. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci2013; 70: 2859–2872.
66.
ArkeliusKWendtTSAnderssonH, et al. LOX-1 and MMP-9 inhibition attenuates the detrimental effects of delayed rt-PA therapy and improves outcomes after acute ischemic stroke. Circ Res2024; 134: 954–969.
67.
AkhmedovABonettiNRReinerMF, et al. Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury. J Cereb Blood Flow Metab2019; 39: 2233–2245.
68.
HsiehFLTurnerLBollaJR, et al. The structural basis for CD36 binding by the malaria parasite. Nat Commun2016; 7: 12837.
69.
SavillJHoggNRenY, et al. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest1992; 90: 1513–1522.
70.
ChoSParkEMFebbraioM, et al. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci2005; 25: 2504–2512.
71.
KunzAAbeTHochrainerK, et al. Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion. J Neurosci2008; 28: 1649–1658.
72.
KimEHTolhurstATSzetoHH, et al. Targeting CD36-mediated inflammation reduces acute brain injury in transient, but not permanent, ischemic stroke. CNS Neurosci Ther2015; 21: 385–391.
73.
RayasamAMottahedinAFaustinoJ, et al. Scavenger receptor CD36 governs recruitment of myeloid cells to the blood–CSF barrier after stroke in neonatal mice. J Neuroinflammation2022; 19: 47.
74.
KimIDJuHMinklerJ, et al. Endothelial cell CD36 mediates stroke-induced brain injury via BBB dysfunction and monocyte infiltration in normal and obese conditions. J Cereb Blood Flow Metab2023; 43: 843–855.
75.
KimETolhurstATQinLY, et al. CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. J Neurosci2008; 28: 4661–4670.
76.
WooMSWangXFaustinoJV, et al. Genetic deletion of CD36 enhances injury after acute neonatal stroke. Ann Neurol2012; 72: 961–970.
77.
FebbraioMPodrezEASmithJD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest2000; 105: 1049–1056.
78.
AgarwalSSahaSGhoshR, et al. Elevated glycosylation of CD36 in platelets is a risk factor for oxLDL mediated platelet activation in type 2 diabetes. FEBS J2023; 291(2): 376–391.
79.
PodrezEAByzovaTVFebbraioM, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med2007; 13: 1086–1095.
80.
WooMSYangJBeltranC, et al. Cell surface CD36 protein in monocyte/macrophage contributes to phagocytosis during the resolution phase of ischemic stroke in mice. J Biol Chem2016; 291: 23654–23661.
81.
JuHKimIDPavlovaI, et al. Ischemic conditioning promotes transneuronal survival and stroke recovery via CD36-mediated efferocytosis. Circ Res2025; 136: e34–e51.
82.
MazzitelliJAPulousFESmythLCD, et al. Skull bone marrow channels as immune gateways to the central nervous system. Nat Neurosci2023; 26(12): 2052–2062.
83.
CugurraAMamuladzeTRustenhovenJ, et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science2021; 373: eabf7844.
84.
CaiWLiuSHuM, et al. Functional dynamics of neutrophils after ischemic stroke. Transl Stroke Res2020; 11: 108–121.
85.
HeWYanLHuD, et al. Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease. MedComm2025; 6: e70063.
86.
CuarteroMIBallesterosIMoragaA, et al. N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARgamma agonist rosiglitazone. Stroke2013; 44: 3498–3508.
FraschSCFernandez-BoyanapalliRFBerryKZ, et al. Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. J Biol Chem2011; 286: 12108–12122.
89.
ZhangZTianHYangC, et al. Mesenchymal stem cells promote the resolution of cardiac inflammation after ischemia reperfusion via enhancing efferocytosis of neutrophils. J Am Heart Assoc2020; 9: e014397.
90.
KaurHPandeyNChandaluriL, et al. Neutrophil integrin alpha9 impairs efferocytosis and worsens long-term recovery after subarachnoid hemorrhage. Arterioscler Thromb Vasc Biol2025; 45(10): e497–e511.
91.
MihailaACCiortanLTucureanuMM, et al. Anti-inflammatory neutrophils reprogram macrophages toward a pro-healing phenotype with increased efferocytosis capacity. Cells2024; 13: 208.
92.
MaoQLuoBMeiJ, et al. Macrophage Dicer promotes tolerogenic apoptotic cell clearance and immune tolerance by inhibiting pentose phosphate pathway activity. Cell Mol Immunol2021; 18: 1841–1843.
93.
WangZLiWLiJ, et al. Neutrophil-modulated Dicer expression in macrophages influences inflammation resolution. Cell Mol Life Sci2025; 82: 114.
94.
ZhaoXTingSMSunG, et al. Clearance of neutrophils from ICH-affected brain by macrophages is beneficial and is assisted by lactoferrin and CD91. Stroke2023; 55(1): 166–176.
95.
Garcia-BonillaLFaracoGMooreJ, et al. Spatio-temporal profile, phenotypic diversity, and fate of recruited monocytes into the post-ischemic brain. J Neuroinflammation2016; 13: 285.
96.
ChenHRSunYYChenCW, et al. Fate mapping via CCR2–CreER mice reveals monocyte-to-microglia transition in development and neonatal stroke. Sci Adv2020; 6: eabb2119.
97.
ZhangXLiHGuY, et al. Repair-associated macrophages increase after early-phase microglia attenuation to promote ischemic stroke recovery. Nat Commun2025; 16: 3089.
98.
BeukerCSchafflickDStreckerJK, et al. Stroke induces disease-specific myeloid cells in the brain parenchyma and pia. Nat Commun2022; 13: 945.
ZarrukJGGreenhalghADDavidS.Microglia and macrophages differ in their inflammatory profile after permanent brain ischemia. Exp Neurol2017; 301(Pt B): 120–132.
101.
GreenhalghADDavidS.Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J Neurosci2014; 34: 6316–6322.
102.
GreenhalghADZarrukJGHealyLM, et al. Peripherally derived macrophages modulate microglial function to reduce inflammation after CNS injury. PLoS Biol2018; 16: e2005264.
103.
HillaAMDiekmannHFischerD.Microglia are irrelevant for neuronal degeneration and axon regeneration after acute injury. J Neurosci2017; 37: 6113–6124.
104.
MildnerASchlevogtBKierdorfK, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer’s disease. J Neurosci2011; 31: 11159–11171.
105.
El KhouryJToftMHickmanSE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med2007; 13: 432–438.
106.
HuXLiPGuoY, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke2012; 43: 3063–3070.
107.
CaoZHarveySSChiangT, et al. Unique subtype of microglia in degenerative thalamus after cortical stroke. Stroke2021; 52: 687–698.
108.
NeherJJEmmrichJVFrickerM, et al. Phagocytosis executes delayed neuronal death after focal brain ischemia. Proc Natl Acad Sci U S A2013; 110: E4098–E4107.
109.
MasudaTAmannLPrinzM.Novel insights into the origin and development of CNS macrophage subsets. Clin Transl Med2022; 12: e1096.
KierdorfKMasudaTJordaoMJC, et al. Macrophages at CNS interfaces: ontogeny and function in health and disease. Nat Rev Neurosci2019; 20: 547–562.
112.
SchonhoffAMFiggeDAWilliamsGP, et al. Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease. Nat Commun2023; 14: 3754.
113.
RajanWDWojtasBGielniewskiB, et al. Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans. Neurobiol Dis2020; 137: 104722.
114.
WangLZhengJZhaoS, et al. CCR2(+) monocytes replenish border-associated macrophages in the diseased mouse brain. Cell Rep2024; 43: 114120.
115.
PedragosaJSalas-PerdomoAGallizioliM, et al. CNS-border associated macrophages respond to acute ischemic stroke attracting granulocytes and promoting vascular leakage. Acta Neuropathol Commun2018; 6: 76.
116.
Vara-PerezMMovahediK.Border-associated macrophages as gatekeepers of brain homeostasis and immunity. Immunity2025; 58: 1085–1100.
117.
TrahtembergUMevorachD.Apoptotic cells induced signaling for immune homeostasis in macrophages and dendritic cells. Front Immunol2017; 8: 1356.
118.
Pujol-AutonellIAmpudiaRMPlanasR, et al. Efferocytosis promotes suppressive effects on dendritic cells through prostaglandin E2 production in the context of autoimmunity. PLoS One2013; 8: e63296.
119.
FelgerJCAbeTKaunznerUW, et al. Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav Immun2010; 24: 724–737.
120.
CarrollSLPasareCBartonGM.Control of adaptive immunity by pattern recognition receptors. Immunity2024; 57: 632–648.
121.
NguyenVACareyLMGiummarraL, et al. A pathway proteomic profile of ischemic stroke survivors reveals innate immune dysfunction in association with mild symptoms of depression—a pilot study. Front Neurol2016; 7: 85.
122.
LoppiSHTavera-GarciaMABecktelDA, et al. Increased fatty acid metabolism and decreased glycolysis are hallmarks of metabolic reprogramming within microglia in degenerating white matter during recovery from experimental stroke. J Cereb Blood Flow Metab2023; 43: 1099–1114.
123.
HuangSCEvertsBIvanovaY, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol2014; 15: 846–855.
124.
BylesVCovarrubiasAJBen-SahraI, et al. The TSC–mTOR pathway regulates macrophage polarization. Nat Commun2013; 4: 2834.
125.
XuXSLiuTChenYJ, et al. MSR1-dependent efferocytosis improved ischemia-reperfusion injury following aged-donor liver transplantation in mice by regulating the pro-resolving polarisation of macrophages. Exp Cell Res2024; 442: 114212.
126.
RiosFJKogaMMPeceninM, et al. Oxidized LDL induces alternative macrophage phenotype through activation of CD36 and PAFR. Mediators Inflamm2013; 2013: 198193.
127.
BouhlelMADerudasBRigamontiE, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab2007; 6: 137–143.
128.
FumagalliSPeregoCPischiuttaF, et al. The ischemic environment drives microglia and macrophage function. Front Neurol2015; 6: 81.
129.
ZhangWZhaoJWangR, et al. Macrophages reprogram after ischemic stroke and promote efferocytosis and inflammation resolution in the mouse brain. CNS Neurosci Ther2019; 25: 1329–1342.
130.
ChangCFGoodsBAAskenaseMH, et al. Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. J Clin Invest2018; 128: 607–624.
131.
GerlachBDAmpomahPBYurdagulAJr, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab2021; 33: 2445–2463.e8.
132.
DenesAVidyasagarRFengJ, et al. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab2007; 27: 1941–1953.
133.
SwirskiFKNahrendorfMEtzrodtM, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science2009; 325: 612–616.
134.
FredmanGKhanS.Specialized pro-resolving mediators enhance the clearance of dead cells. Immunol Rev2023; 319: 151–157.
135.
SerhanCN.Pro-resolving lipid mediators are leads for resolution physiology. Nature2014; 510: 92–101.
136.
MarcheselliVLHongSLukiwWJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem2003; 278: 43807–43817.
137.
WilliamsJJMayurasakornKVannucciSJ, et al. N-3 fatty acid rich triglyceride emulsions are neuroprotective after cerebral hypoxic-ischemic injury in neonatal mice. PLoS One2013; 8: e56233.
138.
MayurasakornKNiatsetskayaZVSosunovSA, et al. DHA but not EPA emulsions preserve neurological and mitochondrial function after brain hypoxia–ischemia in neonatal mice. PLoS One2016; 11: e0160870.
139.
BazanNGEadyTNKhoutorovaL, et al. Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp Neurol2012; 236: 122–130.
140.
ZirpoliHSosunovSANiatsetskayaZV, et al. NPD1 rapidly targets mitochondria-mediated apoptosis after acute injection protecting brain against ischemic injury. Exp Neurol2021; 335: 113495.
141.
HawkinsKEDeMarsKMAlexanderJC, et al. Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A(4) analog: protective mechanisms and long-term effects on neurological recovery. Brain Behav2017; 7: e00688.
142.
HawkinsKEDeMarsKMSinghJ, et al. Neurovascular protection by post-ischemic intravenous injections of the lipoxin A4 receptor agonist, BML-111, in a rat model of ischemic stroke. J Neurochem2014; 129: 130–142.
143.
YinPWeiYWangX, et al. Roles of specialized pro-resolving lipid mediators in cerebral ischemia reperfusion injury. Front Neurol2018; 9: 617.
144.
ZangHJiXYaoW, et al. Role of efferocytosis in chronic pain—from molecular perspective. Neurobiol Dis2025; 207: 106857.
145.
BoucherDMRobichaudSLorantV, et al. Age-related impairments in immune cell efferocytosis and autophagy hinder atherosclerosis regression. Arterioscler Thromb Vasc Biol2025; 45: 481–495.
146.
YurdagulA JrSubramanianMWangX, et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab2020; 31: 518–533.e10.
147.
SchilperoortMNgaiDSukkaSR, et al. The role of efferocytosis-fueled macrophage metabolism in the resolution of inflammation. Immunol Rev2023; 319(1): 65–80.
148.
SchilperoortMNgaiDKaterelosM, et al. PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages. Nat Metab2023; 5: 431–444.
149.
PulestonDJPearceEL.Appetite for arginine: metabolic control of macrophage hunger. Cell Metab2020; 31: 441–442.
150.
AmpomahPBCaiBSukkaSR, et al. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. Nat Metab2022; 4: 444–457.
151.
WangYTTrzeciakAJRojasWS, et al. Metabolic adaptation supports enhanced macrophage efferocytosis in limited-oxygen environments. Cell Metab2023; 35: 316–331.e6.
152.
LiQLiuXDuY, et al. Protocatechuic acid boosts continual efferocytosis in macrophages by derepressing KLF4 to transcriptionally activate MerTK. Sci Signal2023; 16: eabn1372.
153.
WankeFGutbierSRummelinA, et al. Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages. Cell Death Dis2021; 12: 538.
154.
LuoZShengZHuL, et al. Targeted macrophage phagocytosis by Irg1/itaconate axis improves the prognosis of intracerebral hemorrhagic stroke and peritonitis. EBioMedicine2024; 101: 104993.
155.
GrajchenEWoutersEvan de HaterdB, et al. CD36-mediated uptake of myelin debris by macrophages and microglia reduces neuroinflammation. J Neuroinflammation2020; 17: 224.
156.
DehnSThorpEB.Myeloid receptor CD36 is required for early phagocytosis of myocardial infarcts and induction of Nr4a1-dependent mechanisms of cardiac repair. FASEB J2018; 32: 254–264.
157.
AubouyAOlagnierDBertinG, et al. Nrf2-driven CD36 and HO-1 gene expression in circulating monocytes correlates with favourable clinical outcome in pregnancy-associated malaria. Malar J2015; 14: 358.
158.
BallesterosICuarteroMIPradilloJM, et al. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARgamma and 5-LO-dependent pathways. J Leukoc Biol2014; 95: 587–598.
159.
ZhaoJLChenYJYuJ, et al. ISO-alpha-acids improve the hematoma resolution and prevent peri-hematoma inflammations by transforming microglia via PPARgamma-CD36 axis in ICH rats. Int Immunopharmacol2020; 83: 106396.
160.
ChangCFMasseyJOsherovA, et al. Bexarotene enhances macrophage erythrophagocytosis and hematoma clearance in experimental intracerebral hemorrhage. Stroke2020; 51: 612–618.
